胃癌组织中CD44v6和RHAMM的表达及临床意义  

Expressions and clinical significances of CD44v6 and receptor of HA mediated motility in gastric carcinoma

作　　者：张涛[1] 

机构地区：[1]湖北省武汉市中心医院胃肠外科,武汉430014

出　　处：《重庆医科大学学报》2012年第3期216-218,共3页Journal of Chongqing Medical University

摘　　要：目的:探讨CD44v6和HA受体介导的细胞游走受体(Receptor of HA mediated motility,RHAMM)在胃癌组织中的表达情况及其与胃癌临床病理特征、患者预后的关系。方法:采用免疫组化法检测78例胃癌组织和25例正常胃黏膜组织中CD44v6和RHAMM的表达。结果:CD44v6和RHAMM染色均呈黄褐色,CD44v6在胃癌组织中的阳性表达率为64.1%(50/78),而在正常胃黏膜组织中未检测到阳性表达。RHAMM在胃癌组织中的阳性表达率为66.7%(52/78),与正常胃黏膜组织中的阳性表达率12%(3/25)相比,差异有统计学意义(P<0.05)。胃癌组织中CD44v6和RHAMM的表达与患者的性别、年龄、肿瘤大小及肿瘤分化程度无关(均P>0.05)。但CD44v6和RHAMM的表达与肿瘤的浸润深度和淋巴结转移密切相关(均P<0.05)。结论:CD44v6和RHAMM在胃癌中高表达,胃癌细胞可能通过CD44v6和RHAMM促进转移,CD44v6和RHAMM的表达对胃癌的浸润转移有重要作用。Objective：To explore the expressions of CD44v6 and receptor of HA mediated motility（RHAMM） in tissues of gastric carcinoma and their relationship with the clinicopathological features and patients＇ prognosis.Methods：The expression levels of CD44v6 and RHAMM in 78 cases of resected gastric carcinoma tissues and 25 cases of normal gastric mucosal tissues were detected by immunohistochemistry method.Results：Both CD44v6 and RHAMM were expressed as brown granules.The positive rate of CD44v6 expression in gastric carcinoma tissues was 64.1%（50/78）,which was significantly higher than that of 0% in normal tissues（P0.05）.The positive rate of RHAMM expression in gastric carcinoma tissues was 66.7%（52/78）,significantly higher than that of 12%（3/25） in normal tissues（P0.05）.There was no correlation between CD44v6 and RHAMM expressions and the sex,age,tumor size and tumor differentiation（P0.05）.However,the expressions of CD44v6 and RHAMM were closely related with the invasion depth and the extent of lymph node metastasis（P0.05）.Conclusion：Both CD44v6 and RHAMM are highly expressed in gastric carcinoma,which may promote the metastasis of gastric carcinoma cells.The expressions of CD44v6 and RHAMM play an important role in the invasion and metastasis of gastric carcinoma.

关 键 词：胃癌 CD44V6 HA受体介导的细胞游走受体 免疫组化 

分 类 号：R735.2[医药卫生—肿瘤]